SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced the appointment of Kurt Gustafson as Vice President, Finance. Mr. Gustafson will assume the role of Chief Financial Officer on May 15. David Ramsay, Halozyme’s current CFO, will transition to the new position of Vice President, Corporate Development.
